Perhaps FGFR3 expression confirmed by IHC staining could become the routine method for all UC patients; we expect that FGFR3 inhibitors can be considered for perioperative therapy and/or intravesical therapy for patients with UTUC who developed IVR or who progressed to MIBC afterwards since FGFR3 is constantly expressed in these tumor specimens. The gene discussed is FGFR3; the disease is renal pelvis/ureter urothelial carcinoma.